Moderna CEO Stéphane Bancel (via Getty Images)
April 16, 2020 06:00 PM EDTUpdated April 17, 12:15 PM
Deals
Coronavirus

BAR­DA bets $483M on Mod­er­na’s Covid-19 vac­cine as the biotech plots ul­tra-fast PhI­II, re­cruit­ing 150 staffers to scale up 24/7

John Carroll

Editor & Founder

BAR­DA has agreed to gam­ble up to $483 mil­lion on Mod­er­na’s clin­i­cal-stage vac­cine to guard against SARS-CoV-2 — a move that will fund de­vel­op­ment through a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

BioN­Tech set­tles with NIH, UPenn in Covid vac­cine dis­putes and will pay roy­al­ties

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

A service from the Financial Times